Hangeshashinto for refractory overactive bladder

JRCT ID: jRCTs071200035

Registered date:05/10/2020

Basic Information

• Recruitment status: Complete
• Health condition(s) or Problem(s) studied: refractory overactive bladder
• Date of first enrollment: 08/08/2020
• Target sample size: 50
• Study type: Interventional
• Intervention(s): Hangeshashinto (7.5g daily, divide into 3 times) for 12 weeks

Outcome(s)

• Primary Outcome: OABSS total score

Secondary Outcome

IPSS voiding symptom
QOL
Residual urine volume,adverse events

Key inclusion & exclusion criteria

• Age minimum: >= 20age old
• Age maximum: Not applicable
• Gender: Both

Include criteria

1.Aged 20 years or older
2.Patients with refractory overactive bladder
3.Has remaining symptoms(Frequency of the urinary urgency is once a week and OABSS total score >= 3) after anticholinergic or B stimulant drug treatment for 12 weeks or more
4.Written informed consent

Exclude criteria

1.Urinary tract infection
2.Urological malignant cancer
3.Neurogenic bladder
4.Catheterization
5.Lower urinary tract obstruction
6.Heart, liver, and renal dysfunction, or blood abnormalities
7.Primary aldosteronism
8.Myopathy
9.Hypokalemia
10.Allergy to hangeshashinto
11.Elderly, dementia, or hard to answer questions
12.Decision by the attending physician

Related Information

• Primary Sponsor: Miyazato Minoru